Tango Therapeutics TNGX Balance Sheet Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $159.97M+162% | $112.28M+61.5% | $60.91M+9.3% | $41.84M-22.7% | $61M-4.3% | ||
| $222.01M+40.3% | $230.86M+22.5% | $94.47M-60.7% | $141.51M-47.7% | $158.29M-44.0% | ||
| $392.33M+74.4% | $353.76M+32.8% | $163.78M-45.6% | $190.1M-42.1% | $224.93M-36.1% | ||
| $6.38M-15.4% | $6.87M-15.2% | $7.35M-14.5% | $7.79M-14.4% | $7.54M-20.8% | ||
| $435.79M+58.9% | $398.69M+26.0% | $210.14M-40.4% | $237.89M-37.6% | $274.31M-32.5% | ||
| $14.33M-60.1% | $21.68M-43.2% | $18.44M-50.9% | $40.03M-8.8% | $35.92M-16.1% | ||
| $44.29M-58.8% | $52.51M-55.1% | $50.11M-59.3% | $102.94M-23.1% | $107.55M-24.1% | ||
| 400M+100% | 200M+185,085% | 400M+100% | 400M+100% | 200M0.0% | ||
| -$648.67M-19.8% | -$603.15M-20.3% | -$564.4M-21.7% | -$580.29M-33.5% | -$541.43M-32.3% | ||
| $391.51M+135% | $346.18M+73.5% | $160.03M-30.2% | $134.95M-45.5% | $166.76M-36.9% | ||
| $435.79M+58.9% | $398.69M+26.0% | $210.14M-40.4% | $237.89M-37.6% | $274.31M-32.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Can Tango Therapeutics cover its short-term obligations?
- Its current ratio is 27.38 — current assets exceed current liabilities.
- Where does Tango Therapeutics's balance sheet data come from?
- Every line is extracted from Tango Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.